Cotinga Pharmaceuticals Inc. Stock Toronto S.E.

Stocks

COT

CA22675B2021

Biotechnology & Medical Research

OTC Markets Traded
Delayed Toronto S.E. 10:06:48 2020-10-14 EDT 5-day change 1st Jan Change
0.0350 CAD -41.67% Intraday chart for Cotinga Pharmaceuticals Inc. -22.22% -41.67%
Manager TitleAgeSince
Chief Executive Officer 48 2016-06-30
Director TitleAgeSince
Chairman - 2007-02-19
Director/Board Member - 2013-12-04
Director/Board Member 65 2018-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-41.67%-22.22% - - 2.2K
+0.30%+6.93%+57.44%+71.78% 57.28B
-1.92%+6.03%+40.64%+80.66% 54.99B
+0.49%-1.29%+2.86%+425.15% 23.18B
+1.57%-2.35%-22.53%-15.34% 22.59B
-1.13%+1.05%+20.81%-7.73% 20.46B
+0.65%+1.87%+25.64%-30.06% 17.56B
-0.10%+1.88%+34.42%+545.91% 15.67B
-1.30%-5.02%+170.77%+310.94% 14.46B
+2.07%-0.98%+21.43%+179.36% 13.92B
Average -4.12%+1.28%+39.05%+173.41% 26.68B
Weighted average by Cap. -0.23%+2.10%+38.59%+137.08%
Logo Cotinga Pharmaceuticals Inc.
Cotinga Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. The Company's artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds with a high probability of being developed from disease specific drug discovery through chemical optimization and preclinical testing. The CHEMSAS platform technology is designed for small molecules, and as a drug candidate discovery engine can be applied to any disease target with information for the target of interest. Its initial focus is in advancing the treatment of cancer with the Company's lead compound, COTI-2, having a p53-dependent mechanism of action demonstrating selective and potent anti- cancer activity.
Employees
-